⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 25, 2024Korean Journal of GastroenterologyOpen Access

Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea

Hyun Deok Shin Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Hyuk Soo Eun Seok Hyun Kim Byung Seok Lee Hee Bok Chae Seok‐Hwan Kim Myung Joon Song Soon Yeong Ko Suk Bae Kim

View Full Paper

Ask AI

Bookmark

Share

Abstract

This study compared the effectiveness and safety of glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) in real-life clinical practice.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shin et al. (2024) studied this question.

synapsesocial.com/papers/68e72763b6db6435876a1229 https://doi.org/10.4166/kjg.2023.141

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III TrialsEarly-Phase Clinical Trial · 2021 · 7 citations
2Observational, Post-marketing Surveillance of Safety and Effectiveness of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C.Human Clinical Trial · 2026
3A comparison of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for the treatment of hepatitis C infection among people who inject drugs2024
4Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvircohort · 2021 · 20 citations
5Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysisMeta-Analysis · 2025 · 1 citations

More related papers

A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan2019
Real‐world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C‐Registry2019
The Efficacy of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients and the Impact of the COVID-19 Pandemic: Multicenter Real-Life Data2024

More from Korean Journal of Gastroenterology

Clinical Outcomes and Quality of Life after Laparoscopic Nissen Fundoplication for Refractory Gastroesophageal Reflux Disease: A Prospective Cohort Study from VietnamFri,
Endoscopic Treatment of Esophageal Motility Disorders in the Era of POEM: Current Perspectives and Future DirectionsFri,